We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Integer (ITGR) Beats Earnings and Revenue Estimates in Q3
Read MoreHide Full Article
Integer Holdings (ITGR - Free Report) reported adjusted earnings of 83 cents per share in the third quarter of 2016, way better than 58 cents in the year-ago quarter. Meanwhile, earnings beat the Zacks Consensus Estimate of 78 cents.
Revenues surged a massive 136% year over year to $347 million but missed the consensus mark of $348 million.
During the last quarter, Greatbatch Inc. (GB) renamed itself as Integer Holdings and started trading under the symbol “ITGR”. Meanwhile, the company completed Nuvectra (NVTR) spin-off on Mar 14. Thus, the second quarter of 2016 results exclude Nuvectra figures but include results from Lake Region Medical (acquired in Oct 2015). Notably, the company expects 2016 annual net synergies of around $30 million.
Of late, market sentiments have not been very promising for the company as Interger represents a negative one year return of almost 2.5%, comparing unfavorably with the S&P 500’s approximately 1% over the same time frame.
Quarter Details
Post the Lake Region Medical acquisition earlier this year, Integer realigned its product line into four categories – (1) Advanced Surgical, Orthopedics and Portable Medical, (2) Cardio and Vascular, (3) Cardiac/Neuromodulation, and (4) Electrochem.
Advanced Surgical, Orthopedics, and Portable Medical include the legacy Greatbatch Orthopedics and Portable Medical products in addition to Lake Region Medical Advanced Surgical offerings. On a comparable organic constant currency basis, sales at this segment slumped 4%, courtesy of backlog in shipments in connection with product line transfers to the Tijuana and Mexico facilities. Additionally, the price concessions provided to the larger OEM customers in exchange for longer-term contracts was notable.
Cardio and Vascular includes the Vascular product line and the Lake Region Medical Cardio and Vascular sales. On a comparable organic constant currency basis, Cardio and Vascular sales increased 1% compared to the prior year quarter.
Cardiac/Neuromodulation products include the legacy Greatbatch Cardiac/Neuromodulation segment and QiG in addition to the legacy Lake Region Medical Cardiac/Neuromodulation segment. On a comparable basis and at cc, sales increased 2% due to ‘rebound in revenue’ from certain CRM customer programs, which were negatively impacted during the first half of 2016. However, this platform suffered a few headwinds that include reduced shipments in a limited number of CRM customer programs and contractual price reductions.
Electrochem includes the legacy Greatbatch Energy, Military and Environmental product lines. On a comparable basis and at cc, sales declined 26% to $8.9 million, primarily due to the continued impact of the slowdown in the energy markets, which has caused customers to reduce drilling, pipeline inspection and exploration volumes.
The company posted gross margin of 28.3%, flat on a year-over-year basis. Operating expenses, as a percentage of revenues, contracted 360 basis points from the prior-year quarter to 17.6%
Balance Sheet Information
During the third quarter of 2016, the company repaid $12.3 million of its outstanding debt and increased its cash balance by $8.4 million. For the full year, the company repaid $29 million of debt.
Guidance
Integer is maintaining its adjusted comparable basis revenue, net income, and diluted EPS guidance.
Revenues are predicted in the range of $1.375 billion to $1.395 billion on an adjusted comparable basis. Adjusted earnings are expected in the range of $2.60--$2.75 per share for full-year 2016.
Adjusted EBITDA is projected in the band of $285--$395 million. For the full year, management expects to achieve approximately $30 million in synergies, better than $25 million of the annual target.
Zacks Rank & Key Picks
Currently, Integer carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the broader medical sector are Intuitive Surgical Inc. (ISRG - Free Report) , AngioDynamics Inc. (ANGO - Free Report) and Glaukos Corporation (GKOS - Free Report) .
Intuitive Surgical has a long-term expected earnings growth rate of approximately 11.35%. The stock represents an impressive one-year return of approximately 33.04%.
AngioDynamics has a long-term expected earnings growth rate of 15.00%. The company posted a solid one-year return of almost 25.7%.
Glaukos Corporation recorded a stellar one-year return of almost 63.1%. Notably, the company posted positive surprises in the past four quarters, the average being 110.93%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Integer (ITGR) Beats Earnings and Revenue Estimates in Q3
Integer Holdings (ITGR - Free Report) reported adjusted earnings of 83 cents per share in the third quarter of 2016, way better than 58 cents in the year-ago quarter. Meanwhile, earnings beat the Zacks Consensus Estimate of 78 cents.
Revenues surged a massive 136% year over year to $347 million but missed the consensus mark of $348 million.
During the last quarter, Greatbatch Inc. (GB) renamed itself as Integer Holdings and started trading under the symbol “ITGR”. Meanwhile, the company completed Nuvectra (NVTR) spin-off on Mar 14. Thus, the second quarter of 2016 results exclude Nuvectra figures but include results from Lake Region Medical (acquired in Oct 2015). Notably, the company expects 2016 annual net synergies of around $30 million.
Of late, market sentiments have not been very promising for the company as Interger represents a negative one year return of almost 2.5%, comparing unfavorably with the S&P 500’s approximately 1% over the same time frame.
Quarter Details
Post the Lake Region Medical acquisition earlier this year, Integer realigned its product line into four categories – (1) Advanced Surgical, Orthopedics and Portable Medical, (2) Cardio and Vascular, (3) Cardiac/Neuromodulation, and (4) Electrochem.
Advanced Surgical, Orthopedics, and Portable Medical include the legacy Greatbatch Orthopedics and Portable Medical products in addition to Lake Region Medical Advanced Surgical offerings. On a comparable organic constant currency basis, sales at this segment slumped 4%, courtesy of backlog in shipments in connection with product line transfers to the Tijuana and Mexico facilities. Additionally, the price concessions provided to the larger OEM customers in exchange for longer-term contracts was notable.
INTEGER HOLDNGS Price, Consensus and EPS Surprise
INTEGER HOLDNGS Price, Consensus and EPS Surprise | INTEGER HOLDNGS Quote
Cardio and Vascular includes the Vascular product line and the Lake Region Medical Cardio and Vascular sales. On a comparable organic constant currency basis, Cardio and Vascular sales increased 1% compared to the prior year quarter.
Cardiac/Neuromodulation products include the legacy Greatbatch Cardiac/Neuromodulation segment and QiG in addition to the legacy Lake Region Medical Cardiac/Neuromodulation segment. On a comparable basis and at cc, sales increased 2% due to ‘rebound in revenue’ from certain CRM customer programs, which were negatively impacted during the first half of 2016. However, this platform suffered a few headwinds that include reduced shipments in a limited number of CRM customer programs and contractual price reductions.
Electrochem includes the legacy Greatbatch Energy, Military and Environmental product lines. On a comparable basis and at cc, sales declined 26% to $8.9 million, primarily due to the continued impact of the slowdown in the energy markets, which has caused customers to reduce drilling, pipeline inspection and exploration volumes.
The company posted gross margin of 28.3%, flat on a year-over-year basis. Operating expenses, as a percentage of revenues, contracted 360 basis points from the prior-year quarter to 17.6%
Balance Sheet Information
During the third quarter of 2016, the company repaid $12.3 million of its outstanding debt and increased its cash balance by $8.4 million. For the full year, the company repaid $29 million of debt.
Guidance
Integer is maintaining its adjusted comparable basis revenue, net income, and diluted EPS guidance.
Revenues are predicted in the range of $1.375 billion to $1.395 billion on an adjusted comparable basis. Adjusted earnings are expected in the range of $2.60--$2.75 per share for full-year 2016.
Adjusted EBITDA is projected in the band of $285--$395 million. For the full year, management expects to achieve approximately $30 million in synergies, better than $25 million of the annual target.
Zacks Rank & Key Picks
Currently, Integer carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the broader medical sector are Intuitive Surgical Inc. (ISRG - Free Report) , AngioDynamics Inc. (ANGO - Free Report) and Glaukos Corporation (GKOS - Free Report) .
Notably, all the stocks hold a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Intuitive Surgical has a long-term expected earnings growth rate of approximately 11.35%. The stock represents an impressive one-year return of approximately 33.04%.
AngioDynamics has a long-term expected earnings growth rate of 15.00%. The company posted a solid one-year return of almost 25.7%.
Glaukos Corporation recorded a stellar one-year return of almost 63.1%. Notably, the company posted positive surprises in the past four quarters, the average being 110.93%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>